Daihan Pharmaceutical Co.Ltd (023910) - Total Liabilities
Based on the latest financial reports, Daihan Pharmaceutical Co.Ltd (023910) has total liabilities worth ₩50.75 Billion KRW (≈ $34.39 Million USD) as of September 2025. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore investment intensity of Daihan Pharmaceutical Co.Ltd to see how much of total assets are deployed in long-term investments.
Daihan Pharmaceutical Co.Ltd - Total Liabilities Trend (2014–2024)
This chart illustrates how Daihan Pharmaceutical Co.Ltd's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see Daihan Pharmaceutical Co.Ltd assets under control.
Daihan Pharmaceutical Co.Ltd Competitors by Total Liabilities
The table below lists competitors of Daihan Pharmaceutical Co.Ltd ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Chung Lien Transportation Co Ltd
TWO:5604
|
Taiwan | NT$532.26 Million |
|
Cable One Inc
NYSE:CABO
|
USA | $4.30 Billion |
|
Twinhead International Corp
TW:2364
|
Taiwan | NT$1.00 Billion |
|
Pelita Samudera Shipping Tbk PT
JK:PSSI
|
Indonesia | Rp419.43 Billion |
|
Consolidated Finvest & Holdings Limited
NSE:CONSOFINVT
|
India | Rs985.80 Million |
|
Yi Jinn Industrial Co Ltd
TW:1457
|
Taiwan | NT$8.31 Billion |
|
DEVEX Resources Ltd
AU:DEV
|
Australia | AU$2.79 Million |
|
Galantas Gold Corp
V:GAL
|
Canada | CA$3.91 Million |
Liability Composition Analysis (2014–2024)
This chart breaks down Daihan Pharmaceutical Co.Ltd's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Daihan Pharmaceutical Co.Ltd net asset quality index to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 3.55 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.17 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.15 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Daihan Pharmaceutical Co.Ltd's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Daihan Pharmaceutical Co.Ltd (2014–2024)
The table below shows the annual total liabilities of Daihan Pharmaceutical Co.Ltd from 2014 to 2024.
| Year | Total Liabilities | Change |
|---|---|---|
| 2024-12-31 | ₩48.42 Billion ≈ $32.81 Million |
+4.62% |
| 2023-12-31 | ₩46.28 Billion ≈ $31.36 Million |
-10.28% |
| 2022-12-31 | ₩51.58 Billion ≈ $34.96 Million |
-26.03% |
| 2021-12-31 | ₩69.73 Billion ≈ $47.26 Million |
-2.01% |
| 2020-12-31 | ₩71.17 Billion ≈ $48.23 Million |
-11.13% |
| 2019-12-31 | ₩80.08 Billion ≈ $54.27 Million |
-15.17% |
| 2018-12-31 | ₩94.39 Billion ≈ $63.97 Million |
+37.75% |
| 2017-12-31 | ₩68.52 Billion ≈ $46.44 Million |
+1.72% |
| 2016-12-31 | ₩67.36 Billion ≈ $45.65 Million |
+8.67% |
| 2015-12-31 | ₩61.99 Billion ≈ $42.01 Million |
-8.19% |
| 2014-12-31 | ₩67.52 Billion ≈ $45.75 Million |
-- |
About Daihan Pharmaceutical Co.Ltd
Daihan Pharmaceutical Co.,Ltd. engages in the manufacture and sale of therapeutic drugs in South Korea. The company offers various drugs, such as prescription, OTC, and quasi drugs, as well as offers various infusion related solutions. Daihan Pharmaceutical Co.,Ltd. was founded in 1945 and is headquartered in Seoul, South Korea.